菌群移植联合PD-L1抑制剂及化疗治疗三阴性乳腺癌的展望

与其他乳腺癌亚型相比，三阴性乳腺癌(triple-negative breast cancer,TNBC)患者，无论他们的疾病阶段，总是被认为总体生存数据最差。近年来，PD-L1抑制剂联合白蛋白紫杉醇在治疗TNBC已经取得突破性进展，但在治疗过程中药物副作用也极大地限制了化疗的临床应用，造成它在杀伤癌细胞的同时却又损害了人体的健康。目前已有多方面的科研结果证实，平衡的肠道菌群可以增强化疗效果减轻其副作用。菌群移植作为一种新技术在重建胃肠道微生态方面已在国内外一些医疗研究机构广泛开展，本文就菌群移植联合PD-L1抑制剂及化疗治疗三阴性乳腺癌的价值作一综述。

Prospect of fecal microbiota transplantation combined with PD-L1 inhibitors and chemotherapy in the treatment of triple-negative breast cancer

Compared with other breast cancer subtypes,patients with triple-negative breast cancer (TNBC),regardless of their disease stage,are always considered to have the worst overall survival data.In recent years,PD-L1 inhibitors combined with albumin paclitaxel have made breakthrough progress in the treatment of TNBC,but the side effects of drugs in the treatment process have also greatly restricted the clinical application of chemotherapy,causing it to damage cancer cells and damage human health at the same time.Many scientific research results have confirmed that a balanced intestinal flora can enhance the effect of chemotherapy and reduce its side effects.As a new technology,microbial transplantation has been widely carried out in some medical research institutions at home and abroad in the reconstruction of gastrointestinal microecology.This article reviews the value of microbial transplantation combined with PD-L1 inhibitors and chemotherapy for triple negative breast cancer.